{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T04:18:18Z","timestamp":1781410698113,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare eosinophilic disorders are challenging to manage due to their heterogeneity and lack of targeted therapies. Benralizumab, an anti-IL-5 receptor monoclonal antibody approved for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), has not been systematically studied in other eosinophilic conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of benralizumab in adults with rare, non-asthmatic eosinophilic disorders over 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center, prospective, open-label study, 17 adults with diverse eosinophilic diseases received benralizumab 30 mg every 4 weeks for 24 weeks; responders continued up to 52 weeks. The primary endpoint was \u226550% reduction in peripheral eosinophil counts or tissue infiltration. Secondary outcomes included symptom improvement, reduced exacerbations, corticosteroid withdrawal, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 19 enrolled patients, 17 initiated treatment. Sixteen achieved clinical resolution, and all showed complete peripheral eosinophil depletion. Corticosteroids were discontinued in all completers. One patient had a partial response, and one discontinued due to mild, unrelated liver enzyme elevation. No serious adverse events occurred. Relapses were observed after treatment cessation. Efficacy was demonstrated across heterogeneous conditions, including eosinophilic leukemia, folliculitis, vaginitis, and IgG4-related disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Benralizumab is safe, well-tolerated, and effective in diverse rare eosinophilic disorders, enabling corticosteroid discontinuation and symptom control. These findings support its broader therapeutic potential and warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1702989","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:34:30Z","timestamp":1761226470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study"],"prefix":"10.3389","volume":"16","author":[{"given":"Aviv","family":"Talmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Shamriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaarit","family":"Ribak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Aynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meitav Ben","family":"Sion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Forkosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon Y.","family":"Hershko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.smj.0000242863.17778.1d","article-title":"Chronic eosinophilic pneumonia: a review","volume":"100","author":"Alam","year":"2007","journal-title":"South Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaci.2007.10.015","article-title":"Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines","volume":"121","author":"Brasier","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.6.3296","article-title":"A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse","volume":"170","author":"Shen","year":"2003","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1134178","article-title":"Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome","volume":"14","author":"Rubin","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1\u20137","DOI":"10.1136\/jitc-2024-009658","article-title":"Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events","volume":"12","author":"Rubin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.10.001","article-title":"The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases","volume":"70","author":"Shamriz","year":"2021","journal-title":"Allergol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1997.tb00966.x","article-title":"Congenital wells syndrome","volume":"14","author":"Garty","year":"1997","journal-title":"Pediatr Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e15868","DOI":"10.1097\/MD.0000000000015868","article-title":"Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis","volume":"98","author":"Liu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1\u201310","DOI":"10.1093\/ecco-jcc\/jjae130","article-title":"Peripheral Blood Eosinophilia at Diagnosis of Inflammatory Bowel Disease Is Associated With Severe Disease Course: A Nationwide Study From the epi-IIRN Cohort","volume":"19","author":"Yerushalmy-Feler","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.32074\/1591-951X-234","article-title":"Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD)","volume":"113","author":"Villanacci","year":"2021","journal-title":"Pathologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213420.46127.9c","article-title":"Crystal-storing histiocytosis due to massive accumulation of charcot-leyden crystals: a unique association producing colonic polyposis in a 78-year-old woman with eosinophilic colitis","volume":"31","author":"Lewis","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/l7se2n","article-title":"Role of eosinophilia in IgG4-related disease","volume":"40","author":"Ming","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022417","article-title":"How I diagnose and treat myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions","volume":"145","author":"Reiter","year":"2025","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081756","article-title":"Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor","volume":"206","author":"Mori","year":"2009","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00229","article-title":"Basket trials for intractable cancer","volume":"9","author":"Qin","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1702989\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:34:31Z","timestamp":1761226471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1702989\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1702989"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1702989","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1702989"}}